The core business is performing well with accelerating Specialty Medicines and Vaccines growth, but the massive impairments and the costly Nuvalent acquisition ($10.6B) add significant financial noise and debt. Monitor the upcoming Q3 results for initial Nuvalent revenue contribution and the pace of the Accelerate Growth cost savings program, as well as the FDA decision on neladalkib (PDUFA Nov 2026) and bepirovirsen (PDUFA Oct 2026).
Drugs in focus
GSK drug pipeline →Neladalkib
▲ Bullish Named in this 6-K- Impact
- Phase
- Filed/PDUFA (NDA under FDA Priority Review)
- Time to market
- If approved, US launch would follow the November 27, 2026 PDUFA date (~3 months away); approval is not guaranteed.
- Next catalyst
- None dated
What to watchFor GSK shareholders the near-term binary is November 27, 2026: FDA decision on neladalkib (with sibling ROS1 drug zidesamtinib's PDUFA on September 18, 2026 as a read-through). Note the direct equity upside of this drug was already captured, Nuvalent (NUVL) shareholders were cashed out at $124.00/share on July 15, 2026, so any remaining exposure is through mega-cap GSK, where one oncology NDA moves the stock by low single-digit percentages. Watch for FDA advisory-committee activity and any confirmatory-trial requirements before the PDUFA.
- ● Jemperli 5/10 Approved (Phase 3 / registrational Phase 2 for additional indications) Named in filing
- ● Cabenuva 4/10 Approved Named in filing
- ● mocertatug rezetecan 4/10 Phase 3 Named in filing
- ● Trelegy Ellipta 4/10 Approved Named in filing
- ● Utebzi 4/10 Approved (FDA, June 17, 2026) Named in filing
- 11 more · All GSK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 28 $53.71entry
- T+1 · 4mo ago −0.91%α +0.63% · $53.22
- T+5 · 4mo ago −4.10%α −6.37% · $51.51
- T+20 · 3mo ago −3.05%α −6.43% · $52.07
- T+60 · 27d ago −6.87%α −11.22% · $50.02
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK reported Q2 2026 core results with total sales of £8.4 billion (+5% CER) and core EPS of 50.5p (+9% CER), driven by strong Specialty Medicines and Vaccines growth. However, total operating profit plunged 75% to £481 million due to £1.9 billion in impairments, primarily from the failed camlipixant trial, and higher contingent consideration charges. The company reaffirmed 2026 guidance at the upper half of the 3-5% turnover growth range and announced a new 'Accelerate Growth' restructuring program targeting £1.9 billion in annual savings by 2029, alongside the recently closed $10.6 billion Nuvalent acquisition.
Key Facts
- Q2 2026 total sales £8.4 billion, +5% CER; Core operating profit £2.8 billion, +7% CER.
- Total operating profit fell 75% to £481 million, driven by £1.9 billion in impairments (camlipixant £1.3B, Alector £371M).
- Core EPS rose 9% to 50.5p; Total EPS fell 69% to 10.8p.
- 2026 guidance reaffirmed: turnover +3-5% (upper half), Core OP +7-9% (upper half), Core EPS +7-9% (lower half).
- New 'Accelerate Growth' 3-year program targets £1.9B annual savings by 2029 at a cost of £2.4B.
- Completed £2B share buyback program; Q2 dividend of 17p declared.
- Closed $10.6B Nuvalent acquisition on July 15, 2026, adding zidesamtinib (FDA approved) and neladalkib (PDUFA H2 2026).
- Free cash flow of £2.0B in Q2, up 77% YoY; net debt increased to £15.1B.
Financial Impact
Q2 2026 revenue £8.4B (+5% CER); Core operating profit £2.8B (+7% CER); Total operating profit £481M (-75% CER); Core EPS 50.5p (+9% CER); Total EPS 10.8p (-69% CER); Free cash flow £2.0B (+77% YoY)
Risk Factors
- Execution risk on the Accelerate Growth restructuring program and achieving £1.9B in savings by 2029.
- Integration and pipeline risk from the $10.6B Nuvalent acquisition, which adds debt and dilutes near-term earnings.
- Ongoing legal overhang from Zantac appeals (14,000 cases) and potential generic competition for Trelegy Ellipta.
- Currency headwinds from a strengthening GBP, estimated to reduce 2026 turnover growth by -2% and Core OP growth by -4%.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006949 |
| Document: 0001654954-26-006949-index-headers.html | 0001654954-26-006949 |
| Document: 0001654954-26-006949-index.html | 0001654954-26-006949 |
| Document: 0001654954-26-006949.txt | 0001654954-26-006949 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers